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Background:  EVEREST II REALISM is a prospective, multi-center, continued access study to collect data on “real world” use of MitraClip 
in both high risk (HR) and non-high risk (NHR) patients. Preliminary 1-year outcomes are presented.
methods:  HR was defined as STS score ≥12% or pre-specified risk factors. As of December 2013, 628 HR and 271 NHR patients were 
enrolled. Echocardiograms were evaluated by an independent core lab. Clinical outcomes at 1 year included change in left ventricular (LV) 
volume, NYHA Functional Class and quality of life.
results:  Mean ages of HR and NHR patients were 77 and 74 years respectively. Baseline co-morbidities prevalent in both groups 
included CAD, atrial fibrillation and diabetes. Baseline LVEF was 47±14% in HR and 56±11% in NHR. Mortality at 30 days was 4.2% in HR 
and 1.5% in NHR. Despite advanced age and burden of co-morbidities, 89% of all patients achieved MR reduction to ≤2+ post-procedure 
and 90% were discharged home. At 1 year, patients showed improvements from baseline in clinical and functional measures.
conclusion:  In EVEREST II REALISM, patients treated with MitraClip are elderly and have significant co-morbidities. In this population, 
the MitraClip procedure is a safe option that provides meaningful clinical and functional improvements at 1 year. Analysis of the final 1-year 
results will be presented.
Study funded by Abbott Vascular.
Baseline characteristics and outcomes* in EVEREST II REALISM
EVEREST II REALISM (n=899)
High Risk Arm
(n=628)
Non-High Risk Arm
(n=271)
Age 77 ± 11 years 74 ± 11 years
Coronary Artery Disease 78% 49%
Atrial Fibrillation 71% 56%
Diabetes 37% 19%
Prior CABG Surgery 54% 17%
Functional MR 70% 32%
LV Ejection Fraction 47 ± 14 % 56 ± 11 %
Mortality at 1 year 23.0% 10.0%
Freedom from MR > 2+ at 1 year in surviving patients 83% 83%
Change in LVEDV (1 Year minus Baseline) -8 ± 35 ml -13 ± 24 ml
Change in SF-36 PCS at 1 year (1 Year minus Baseline) +5.0 ± 9.9 points +6.2 ± 9.4 points
NYHA Functional Class III/IV: Baseline→1 year 81%→15% 51%→9%
*Echo data pending final core lab review; adverse event data pending final CEC adjudication.
Continuous variables expressed as mean +/- SD. Changes from baseline to 1 year reported in survivors with paired data.
